ArticleFrontiers in oncology2021

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Gang Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.